I must say I like the extra nuggets slipped into the PR as well. MHRA asked about our severe interim analysis so they are keeping their eye on it. Of course we don't know what cydy was able to tell them other than what we already know. And monotherapy label expansion. I guess it wasn't mentioned if a pivotal trial would be necessary or perhaps the MHRA encouraged them to submit what they already have on monotherapy for label expansion and that would be enough. Hoping it's the latter of those two. That's a nice double whammy. Canada your next.